ANAPTYSBIO, INC: Big Changes Ahead – What You Need to Know

If you follow AnaptysBio, you have likely seen the major headlines. The company is splitting into two, and we now have the final details on this "reset."

1. What is happening?

AnaptysBio is spinning off an independent company called First Tracks Biotherapeutics (ticker: "TRAX").

Think of this as a business split that lets both sides focus on different goals:

• First Tracks (TRAX): This company will develop new drugs for autoimmune and inflammatory diseases. They are launching with $180 million in cash—$100 million from AnaptysBio’s current bank account and $80 million raised from private investors.
• AnaptysBio (ANAB): This company will remain independent. It will focus on managing its existing royalty income—specifically from its partnership with GSK for JEMPERLI (dostarlimab)—and protecting its patents.

2. Key Dates for Your Calendar

• April 6, 2026 (Record Date): If you own AnaptysBio shares by the market close (4:00 PM ET) on this day, you will receive shares of the new company.
• April 20, 2026 (Distribution Date): You will receive one share of "TRAX" for every share of "ANAB" you own. "TRAX" will begin trading on the Nasdaq that morning.

3. Why is this happening?

Biotech companies often split to help their drug programs grow faster. By separating, the two teams can focus their budgets and research without the distraction of a combined organization. First Tracks is starting with three drug candidates in Phase 2 clinical trials. They have enough cash to fund operations through mid-2028, giving them two years to reach key research milestones.

4. What does this mean for you?

• Your Portfolio: You do not need to do anything. You will not pay for these new shares, and you do not need to trade your current ones. Your brokerage account will automatically update to show both ANAB and TRAX shares.
• The Tax Man: Note that this distribution is expected to be a taxable event. It will be treated as a dividend based on the value of the TRAX shares when they are distributed. Check with a tax professional to see how this affects your specific tax situation.
• The Strategy: This is a "clean slate" move. By bringing in new leadership—like incoming CFO Ajim Tamboli—and separating the research-heavy side of the business from the royalty-generating side, the company hopes to make it easier for investors to value each part of the business separately.

5. What should you do?

• Watch the Ticker: Keep an eye on "TRAX" once it starts trading on April 20th. Prices often swing as institutional investors adjust their holdings.
• Check Your Broker: If you sell your ANAB shares between April 6th and April 20th, you may be selling your right to receive the TRAX shares. Call your broker to confirm if your sale includes these rights.
• Stay Calm: Splits are common in biotech. They simply allow AnaptysBio to operate as a leaner, royalty-focused entity while First Tracks pursues high-growth clinical development.

---

Disclaimer: I am an AI, not a financial advisor. This summary is for informational purposes only. The spin-off is a taxable event, so please consult with a tax professional or your broker regarding your specific portfolio.